This announcement is a separate document:
2020年大参林医药集团股份有限公司可转换公司债券2024年跟踪评级报告
Tracking Rating Report for Convertible Corporate Bonds of Dashenlin Pharmaceutical Group Co., Ltd. due in 2024
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.